ADASUVE

Brand name authorized in: Austria Spain Hong Kong Ireland Lithuania Poland United Kingdom United States

Active ingredients

The drug ADASUVE contains one active pharmaceutical ingredient (API):

1 Loxapine
UNII LER583670J - LOXAPINE

Loxapine binds with noradrenergic, histaminergic, and cholinergic receptors, and its interaction with these systems may influence the spectrum of its pharmacological effects. Loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.

Read about Loxapine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Loxapine
N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AH Diazepines, oxazepines and thiazepines
Discover more medicines within N05AH01

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
Summary of product characteristics (SPC)

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
ES
Centro de información online de medicamentos de la AEMPS
Identifier(s): 113823002
GB
Medicines & Healthcare Products Regulatory Agency
Identifier(s): 326880
HK
Department of Health Drug Office
Identifier(s): 67228
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1069358, 1069359, 1072654, 1072655
PL
Rejestru Produktów Leczniczych
Identifier(s): 100308516, 100308522
US
FDA, National Drug Code
Identifier(s): 10885-003